In:
Multiple Sclerosis Journal, SAGE Publications, Vol. 26, No. 10 ( 2020-09), p. 1264-1266
Kurzfassung:
Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic. Methods: We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy. Results: Despite a severe lymphopenia (absolute lymphocyte count 240/µL), the patient had a moderate course of COVID-19. Conclusion: Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia.
Materialart:
Online-Ressource
ISSN:
1352-4585
,
1477-0970
DOI:
10.1177/1352458520943783
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2020
ZDB Id:
2008225-3